Cara Therapeutics (CARA) and Tvardi Therapeutics Announce Entry into Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024 7:00 AM ESTProposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardis existing cash and Caras anticipated cash balance, is expected to fund the combined company into the second half of 2026
Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma
... More